BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 17181595)

  • 1. Impact of nonmyeloablative conditioning regimens on the occurrence of pure red cell aplasia after ABO-incompatible allogeneic haematopoietic stem cell transplantation.
    Malfuson JV; Amor RB; Bonin P; Rodet M; Boccaccio C; Pautas C; Kuentz M; Cordonnier C; Noizat-Pirenne F; Maury S
    Vox Sang; 2007 Jan; 92(1):85-9. PubMed ID: 17181595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation.
    Griffith LM; McCoy JP; Bolan CD; Stroncek DF; Pickett AC; Linton GF; Lundqvist A; Srinivasan R; Leitman SF; Childs RW
    Br J Haematol; 2005 Mar; 128(5):668-75. PubMed ID: 15725089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.
    Canals C; Muñiz-Díaz E; Martínez C; Martino R; Moreno I; Ramos A; Arilla M; Boto N; Pastoret C; Remacha A; Sierra J; Madoz P
    Transfusion; 2004 Nov; 44(11):1603-11. PubMed ID: 15504166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption.
    Rabitsch W; Knöbl P; Prinz E; Keil F; Greinix H; Kalhs P; Worel N; Jansen M; Hörl WH; Derfler K
    Bone Marrow Transplant; 2003 Nov; 32(10):1015-9. PubMed ID: 14595389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pure red cell aplasia after allogeneic stem cell transplantation with reduced conditioning.
    Veelken H; Wäsch R; Behringer D; Bertz H; Finke J
    Bone Marrow Transplant; 2000 Oct; 26(8):911-5. PubMed ID: 11081395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk.
    Dahl D; Hahn A; Koenecke C; Heuft HG; Dammann E; Stadler M; Buchholz S; Krauter J; Eder M; Sykora KW; Klein C; Ganser A; Sauer M
    Transfusion; 2010 Mar; 50(3):649-55. PubMed ID: 19929861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation.
    Fang B; Song Y; Li N; Li J; Han Q; Zhao RC
    Ann Hematol; 2009 Mar; 88(3):261-6. PubMed ID: 18769919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
    Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
    Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation].
    Huang XJ; Liu DH; Xu LP; Han W; Jiang Q; Chen YH; Zhang YC; Liu KY; Bao L; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Sep; 26(9):548-50. PubMed ID: 16468333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.
    Helbig G; Stella-Holowiecka B; Wojnar J; Krawczyk M; Krzemien S; Wojciechowska-Sadus M; Markiewicz M; Wylezol I; Kopera M; Holowiecki J
    Ann Hematol; 2007 Sep; 86(9):677-83. PubMed ID: 17486341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.
    Mueller RJ; Stussi G; Odermatt B; Halter J; Schanz U; Seebach JD
    Xenotransplantation; 2006 Mar; 13(2):126-32. PubMed ID: 16623806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.
    Helbig G; Stella-Holowiecka B; Krawczyk-Kulis M; Wojnar J; Markiewicz M; Wojciechowska-Sadus M; Kopera M; Kruzel T; Najda J; Nowak K; Holowiecki J
    Haematologica; 2005 Nov; 90 Suppl():ECR33. PubMed ID: 16266924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation.
    Bolan CD; Leitman SF; Griffith LM; Wesley RA; Procter JL; Stroncek DF; Barrett AJ; Childs RW
    Blood; 2001 Sep; 98(6):1687-94. PubMed ID: 11535498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ABO incompatibility and non myeloablative allogeneic stem cell transplantation].
    Malfuson JV; Hicheri Y; Bonin P; Rodet M; Boccaccio C; Pautas C; Kuentz M; Cordonnier C; Noizat-Pirenne F; Maury S
    Transfus Clin Biol; 2007 Aug; 14(3):327-33. PubMed ID: 17462938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pure red cell aplasia after allogeneic transplantation of ABO incompatible hematopoietic stem cells].
    Bullorsky E; Shanley C; Stemmelin G; Ceresetto J; Rabinovich O
    Medicina (B Aires); 2002; 62(6):575-7. PubMed ID: 12532694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of pure red cell aplasia after major ABO-incompatible peripheral blood stem cell transplantation by induction of chronic graft-versus-host disease.
    Yamaguchi M; Sakai K; Murata R; Ueda M
    Bone Marrow Transplant; 2002 Oct; 30(8):539-41. PubMed ID: 12379896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation.
    Lee JH; Lee KH; Kim S; Lee JS; Kim SH; Kwon SW; Kim WK
    Bone Marrow Transplant; 2000 Jan; 25(2):179-84. PubMed ID: 10673677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation.
    Ozkurt ZN; Yegin ZA; Yenicesu I; Aki SZ; Yagci M; Sucak GT
    Transplant Proc; 2009 Nov; 41(9):3851-8. PubMed ID: 19917400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
    Zhu KE; Li JP; Zhang T; Zhong J; Chen J
    Hematology; 2007 Apr; 12(2):117-21. PubMed ID: 17454192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.